Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Anagenics Ltd
Angionetics Inc
AstraZeneca Plc
BioCardia Inc
Chrysalis BioTherapeutics Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Imbria Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
NervGen Pharma Corp
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc